Early Detection of Prostate Cancer, An Issue of Urologic Clinics
Early Detection of Prostate Cancer, An Issue of Urologic Clinics

Author: Stacy Loeb

Publisher: Elsevier Health Sciences

Published: 2014-05-28

Total Pages: 145

ISBN-13: 0323297269

DOWNLOAD EBOOK

PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.

Early Detection of Prostate Cancer, an Issue of Urologic Clinics
Early Detection of Prostate Cancer, an Issue of Urologic Clinics

Author: Stacy Loeb

Publisher: Clinics: Internal Medicine

Published: 2014-04-25

Total Pages: 0

ISBN-13: 9780323297257

DOWNLOAD EBOOK

PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.

Prostate Cancer, An Issue of Urologic Clinics, E-Book
Prostate Cancer, An Issue of Urologic Clinics, E-Book

Author: Marc A. Bjurlin

Publisher: Elsevier Health Sciences

Published: 2017-11-06

Total Pages:

ISBN-13: 0323549063

DOWNLOAD EBOOK

Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer. He has assembled top experts to address the latest advances in the diagnosis and treatment of prostate cancer. Articles are devoted to the following topics: Whom to Biopsy: Pre-Diagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators; How to Biopsy: Transperineal vs. Tranrectal, Saturation vs. Targeted: What’s the Evidence; Pre-Diagnostic Risk and Assessment with Imaging and Image-guided Biopsy; Whom to treat: Post-Diagnostic Risk Assessment with Gleason score, Risk Models, and Genomic Classifier; Strategies for Staging and Utilization of Imaging; Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes; Focal Ablation of Early Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome; Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-based Approach; How to Radiate the Prostate: Hypofractionation, Sterotactic Body Radiation Therapy, and Conventional Intensity-Modulated Radiotherapy; Managing Relapse after Surgical Therapy: Adjuvant vs. Salvage Therapy; Newly diagnosed Metastatic Prostate Cancer – Has the Paradigm Changed; Role of Local therapy in Oligometastatic Prostate Cancer: Should we Expect Cure; Approaching the High-Risk Patient; and Castration-Resistant Prostate Cancer: An Algorithmic Approach. Readers will come away with state-of-the-art information on strategies for diagnosing, treating, and managing prostate cancer.

Prostate Cancer Screening
Prostate Cancer Screening

Author: Donna Pauler Ankerst

Publisher: Springer Science & Business Media

Published: 2009-01-24

Total Pages: 391

ISBN-13: 160327281X

DOWNLOAD EBOOK

More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world’s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world’s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.

Prostate Cancer Genetics: Changing the Paradigm of Care, An Issue of Urologic Clinics
Prostate Cancer Genetics: Changing the Paradigm of Care, An Issue of Urologic Clinics

Author: Leonard G. Gomella

Publisher: Elsevier

Published: 2021-08-28

Total Pages: 240

ISBN-13: 9780323791670

DOWNLOAD EBOOK

In this issue of Urologic Clinics, guest editors Leonard G. Gomella and Veda Giri bring their considerable expertise to the topic of Prostate Cancer Genetics: Changing the Paradigm of Care. Provides in-depth, clinical reviews on Prostate Cancer Genetics, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

Management of Prostate Cancer
Management of Prostate Cancer

Author: Eric A. Klein

Publisher: Springer Science & Business Media

Published: 2004-05-07

Total Pages: 735

ISBN-13: 1592597769

DOWNLOAD EBOOK

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that